Natera, Inc.
NTRAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Natera, Inc. focuses on Diagnostics & Research services and products. Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. The $47.31B market capitalization puts NTRA squarely in large-cap range for its industry. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Market Cap
$47.31B
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-3679.15
EPS (TTM)
$-1.35
EPS (Fwd)
$-0.09
ROE
-12.5%
ROA
-8.1%
Cash
$1.09B
Total Debt
$238.5M
Free CF
$104.0M
52W Change
86.1%
Annual Financials
Cash vs Debt
Where NTRA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NTRA finished 38.60% above its 150-day moving average ($234.61) and 38.71% above its 200-day moving average ($234.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTRA overbought or oversold?
At the September 3, 2026 close, NTRA's RSI(14) was 60.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.09B in cash comfortably exceeding the $238.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $104.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -12.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $820.2M (2022) to $2.31B (2025), reflecting a 181% increase over the period.
Natera, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NTRA.